Findings from two studies highlight that mortality rates are elevated among patients with Cushing’s syndrome compared with healthy individuals, and this increased risk is attenuated, but still significant, in those who have achieved remission.
The European Reference Network on Rare Endocrine Conditions surveyed the prevention of venous thromboembolism in Cushing’s syndrome patients in European reference centers. Read the Publication Highlight to see the results reported by van Haalen et al. on behalf of the Endo-ERN Cushing and Thrombosis Study Group.
Treatment with the 11β-hydroxylase inhibitor osilodrostat normalizes cortisol levels in the majority of patients with Cushing’s disease, report Mônica Gadelha and co-investigators from the LINC 4 trial.